8/3/2012 9:22:16 AM
BERKELEY, Calif., Aug. 3, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today its partner Les Laboratoires Servier (Servier) and the Company have entered into an agreement with Boehringer Ingelheim to transfer XOMA's technology and process for the commercial manufacture of gevokizumab, XOMA's novel interleukin 1-beta (IL-1ß) allosteric modulating antibody. Gevokizumab currently is in Phase 3 clinical development in patients with non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye. The global development plan includes a Phase 3 trial to be conducted by Servier in patients with Behçet's uveitis. Upon completion of the transfer and the establishment of biological comparability, Boehringer Ingelheim is expected to produce gevokizumab at its facility in Biberach, Germany, for XOMA's commercial use. XOMA and Servier retain all rights to the development and commercialization of gevokizumab. Financial terms of the agreement were not disclosed.
comments powered by